Peptides will mess with your hormones long-term

This objection treats the corpus as a single endocrine intervention. It is not. Different peptide classes interface with different endocrine axes, and the long-term concern flows class-by-class rather than as a blanket property of the category. The GH secretagogue class — Ipamorelin, CJC-1295, Tesamorelin, MK-677 — raises growth hormone and downstream IGF-1. Sustained IGF-1 elevation is the load-bearing concern, and it is shared with growth-hormone replacement therapy itself. The cancer-mechanism caution that applies to GHRT applies here. There is also a class concern about modest insulin-sensitivity decreases (well-documented in the MK-677 Nass 2008 trial — fasting glucose +0.3 mmol/L over two years). Cycling, biomarker monitoring (fasting glucose, IGF-1, lipid panel), and clinician oversight rather than open-ended self-administration are the practitioner-default frame. The metabolic / GLP-1 class — Semaglutide, Tirzepatide, Retatrutide — produces sustained GLP-1 receptor activation and, for the dual / triple agonists, GIP and glucagon receptor activation. The long-term data on GLP-1 agonists is now substantial (decades for liraglutide, exenatide, dulaglutide). Pancreatitis, gallbladder disease, and the medullary thyroid carcinoma boxed warning (based on rodent C-cell data) are recognized; the long-tail signals — NAION, gastroparesis severity, suicidal ideation — are still maturing in the literature. The discontinuation pattern is also part of the endocrine story: in the STEP 1 extension (Wilding et al. 2022), participants regained roughly two-thirds of their lost weight within a year off-treatment, with cardiometabolic improvements reverting in parallel. That is an endocrine effect; whether it is a *concerning* one depends on framing. The cognitive class (Selank, Semax, Dihexa) and the immune class (Thymosin α-1, KPV) interact with their respective regulatory systems, but the magnitude and nature of the interaction is much smaller than the GH or GLP-1 cases. Selank does not chronically suppress neurotransmitter systems; KPV's NF-κB-suppressive activity is at nanomolar concentrations and at short time-scales. Treating these as equivalent endocrine interventions to Tesamorelin or Semaglutide is a category error. The longevity / mitochondrial class (MOTS-c, Epitalon, SS-31) interfaces with cellular-metabolism signaling rather than the classical endocrine axes. The long-term human data here is genuinely absent, and "the long-term effects are not characterized" is the honest answer for any of these used chronically in healthy adults — the SS-31 MMPOWER-3 negative result and Khavinson's Russian Epitalon literature do not constitute a long-term human safety database for self-administering biohackers. Where the critic has a real point: anyone using a GH-axis peptide chronically without periodic IGF-1 monitoring, or layering a GLP-1 agonist into a stack with insulin or sulfonylureas without clinician oversight, is operating outside the safety frame the trial evidence supports. The endocrine concerns for those specific classes are real and class-defined. For the longevity / mitochondrial peptides, the absence of long-term data is a legitimate worry — not because the literature shows they cause harm, but because the timescales involved exceed what the evidence has been able to rule out. Where the critic loses the thread: applying the GH-axis or GLP-1 endocrine concerns uniformly across "peptides" produces a sentence that overstates the risk for low-dose KPV used for gut symptoms while understating the legitimate concern about long-term Tesamorelin use outside its approved indication. Class-specific framing is what the underlying biology actually supports.